- AU$2.51bn
- AU$2.52bn
- $17.20m
Brief: Mesoblast Seeks Trading Halt
Australia's Mesoblast gains as quarterly loss narrows
Brief: Mesoblast Posts Qtrly Loss After Tax $18.6 Mln
Australia's Mesoblast drops most in 10 months on discounted placement
Brief: Mesoblast Says Completed Global Private Placement Raising About $40 Mln
Brief: Mesoblast Ltd Seeks Trading Halt
Brief: Mesoblast Ltd Files Prospectus Relates To Offer, Sale From Time To Time By Oaktree Shareholders Of Up To 2.3 Million Ordinary Shares
Australia's Mesoblast jumps as USFDA plans inspection of its cell therapy ops
Brief: Mesoblast Says FDA Schedules Pre-License Inspection Of Remestemcel-L Manufacturing
Mesoblast gains on FDA nod to review lead drug candidate
Mesoblast soars on U.S. FDA's nod to review lead drug candidate
Brief: Mesoblast Says U.S. FDA Accepts Co's BLA Resubmission For Remestemcel
Australia's Mesoblast eyes best day in 2-1/2 years after FDA update
Austalia's Mesoblast rises most in three weeks as Q2 loss narrow
Brief: Mesoblast Says QTRLY Loss Attributable $24.5 Million
Brief: Dream-Hf Phase 3 Trial Results For Mesoblast Cell Therapy In Heart Failure Published In Journal Of The American College Of Cardiology (Jacc)
Australia's Mesoblast jumps on FDA designation for back-pain medicine
Brief: Mesoblast Says Regenerative Medicine Advanced Therapy Designation granted For Rexlemestrocel-L
Mesoblast up as co resubmits marketing application for systemic disorder drug